LGND4:00 AMLigand Announces Pricing of Upsized $625 Million Convertible Senior Notes Offeringligand.com
LGND7:00 AMLigand Announces Proposed Offering of $550 Million of Convertible Senior Notes Due 2031ligand.com
LGND7:00 AMLigand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregatorligand.com
LGND7:00 AMLigand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGSligand.com